{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:07:36Z","timestamp":1792976856417,"version":"4.5.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Bromodomain-containing protein 4 (BRD4), a component of the bromodomain and extraterminal domain (BET) family, acts as a scaffold for transcription factors at promoters and super-enhancers, with the downstream effect of positively regulating the activity of signaling pathways, which sustain the inflammatory properties of immune cells and the expression of oncogens. These discoveries have boosted an intensive experimental work aimed at exploring the involvement of BRD4 in the pathogenesis of immune-mediated diseases and malignancies. As a result of these studies, there has been a considerable interest in the development of BRD4 inhibitors, which are now ready to be tested in clinical trials. In this article, we review the data about the expression and role of BRD4 in patients with Crohn\u2019s disease and patients with ulcerative colitis, the major human inflammatory bowel diseases (IBD), as well as in patients with colorectal cancer (CRC). We also discuss the more recent data supporting the therapeutic benefit of BRD4 inhibitors in both IBD- and CRC-like mouse models.<\/jats:p>","DOI":"10.3389\/fphar.2025.1682223","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:54:26Z","timestamp":1762941266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Bromodomain-containing 4 as a therapeutic target in inflammatory bowel diseases and colorectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Irene","family":"Marafini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Frascatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"De Cristofaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol. Oncol."},{"key":"B2","first-page":"530","article-title":"Degradation of Brd4 - a promising treatment approach not only for hematologic but also for solid cancer","volume":"11","author":"Bauer","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-021-00366-w","article-title":"Cancer stem cell-immune cell crosstalk in tumour progression","volume":"21","author":"Bayik","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA a cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1053\/j.gastro.2009.02.049","article-title":"Interleukin-25 inhibits Interleukin-12 production and Th1 cell-driven inflammation in the gut","volume":"136","author":"Caruso","year":"2009","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1073\/pnas.1615601114","article-title":"Bet N-Terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice","volume":"114","author":"Cheung","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"Bet bromodomain inhibition as a therapeutic strategy to target C-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"Brd4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/MCB.20.17.6537-6549.2000","article-title":"A bromodomain protein, mcap, associates with mitotic chromosomes and affects G(2)-to-M transition","volume":"20","author":"Dey","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The myc oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"173500","DOI":"10.1016\/j.ejphar.2020.173500","article-title":"Synergistic antitumor activity of dha and Jq1 in colorectal carcinoma","volume":"885","author":"Ding","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"106767","DOI":"10.1016\/j.phrs.2023.106767","article-title":"Brd4: new hope in the battle against glioblastoma","volume":"191","author":"Duan","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/0008-5472.CAN-11-3893","article-title":"Gastrointestinal adenocarcinomas of the esophagus, stomach, and Colon exhibit distinct patterns of genome instability and oncogenesis","volume":"72","author":"Dulak","year":"2012","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MIB.0000000000000236","article-title":"Cytokines, ibd, and colitis-associated cancer","volume":"21","author":"Francescone","year":"2015","journal-title":"Inflamm. bowel Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/ecco-jcc\/jjae104","article-title":"Bromodomain-containing 4 is a positive regulator of the inflammatory cytokine response in the gut","volume":"18","author":"Franze","year":"","journal-title":"J. Crohn's & colitis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3390\/cells13201698","article-title":"Bromodomain-containing 4 is a positive regulator of Interleukin-34 production in the gut","volume":"13","author":"Franze","year":"","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1158\/0008-5472.CAN-21-0649","article-title":"Mir-766-5p targets super-enhancers by downregulating cbp and Brd4","volume":"81","author":"Gen","year":"2021","journal-title":"Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/biomedicines6010016","article-title":"BET family protein BRD4: an emerging actor in NF\u03baB signaling in inflammation and cancer","volume":"6","author":"Hajmirza","year":"2018","journal-title":"Biomedicines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ceb.2013.01.007","article-title":"Epigenetic regulation of Colon cancer and intestinal stem cells","volume":"25","author":"Hammoud","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","article-title":"Mdm2-Recruiting protac offers superior, synergistic antiproliferative activity Via simultaneous degradation of Brd4 and stabilization of P53","volume":"79","author":"Hines","year":"2019","journal-title":"Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 coactivates transcriptional activation of Nf-Kappab via specific binding to acetylated rela","volume":"29","author":"Huang","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1158\/1078-0432.CCR-08-1596","article-title":"Colon cancer: it's Cin or cimp","volume":"14","author":"Issa","year":"2008","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1124\/mol.117.110379","article-title":"Rvx-297, a bet bromodomain inhibitor, has therapeutic effects in preclinical models of acute inflammation and autoimmune disease","volume":"92","author":"Jahagirdar","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"117933","DOI":"10.1016\/j.biopha.2025.117933","article-title":"Kb-0118, a novel bet Bromodomain inhibitor, suppresses Th17-Mediated inflammation in inflammatory bowel disease","volume":"185","author":"Jeong","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e00573-17","DOI":"10.1128\/MCB.00573-17","article-title":"Depletion of mediator kinase module subunits represses superenhancer-associated genes in Colon cancer cells","volume":"38","author":"Kuuluvainen","year":"2018","journal-title":"Mol. Cell Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.5483\/bmbrep.2017.50.12.194","article-title":"JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-\u03baB axis","volume":"50","author":"Lee","year":"2017","journal-title":"BMB Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14728222.2023.2175317","article-title":"Bromodomain-containing protein 4 (Brd4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics","volume":"27","author":"Ma","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"B31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.apha.2024.10.008","article-title":"Brd4 as an emerging epigenetic therapeutic target for inflammatory bowel disease","volume":"101","author":"Ma","year":"2024","journal-title":"Adv. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1021\/acsptsci.5c00068","article-title":"Orally bioavailable Brd4 Bd1 inhibitor Zl0516 effectively suppresses colonic inflammation in animal models of inflammatory bowel disease","volume":"8","author":"Ma","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/14712598.2019.1652267","article-title":"Inflammatory cytokines: from discoveries to therapies in ibd","volume":"19","author":"Marafini","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1549193","DOI":"10.3389\/fimmu.2025.1549193","article-title":"High Smad7 marks inflammation in patients with chronic pouchitis","volume":"16","author":"Maresca","year":"2025","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI83265","article-title":"Ccat1 is an enhancer-templated Rna that predicts bet sensitivity in colorectal cancer","volume":"126","author":"McCleland","year":"2016","journal-title":"J. Clin. investigation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/0022034514534261","article-title":"Bet inhibitor Jq1 blocks inflammation and bone destruction","volume":"93","author":"Meng","year":"2014","journal-title":"J. Dent. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1053\/j.gastro.2005.09.005","article-title":"Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease","volume":"129","author":"Monteleone","year":"2005","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"103410","DOI":"10.1016\/j.autrev.2023.103410","article-title":"Immune-mediated inflammatory diseases: common and different pathogenic and clinical features","volume":"22","author":"Monteleone","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","article-title":"Enhancers are activated by P300\/Cbp activity-dependent pic assembly, rnapii recruitment, and pause release","volume":"81","author":"Narita","year":"2021","journal-title":"Mol. Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm0996-998","article-title":"Local administration of antisense phosphorothioate oligonucleotides to the P65 subunit of Nf-Kappa B abrogates established experimental colitis in mice","volume":"2","author":"Neurath","year":"1996","journal-title":"Nat. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/gut.43.6.856","article-title":"Role of Nf-Kappab in immune and inflammatory responses in the gut","volume":"43","author":"Neurath","year":"1998","journal-title":"Gut"},{"key":"B42","doi-asserted-by":"publisher","first-page":"110358","DOI":"10.1016\/j.jbc.2025.110358","article-title":"BET bromodomain inhibitors attenuate transcription of a subset of IL-1-induced NF-\u03baB targets that promote inflammation in \u03b2-cells","volume":"301","author":"Nord","year":"2025","journal-title":"J. Biol. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2353\/jmoldx.2008.070082","article-title":"Molecular classification and correlates in colorectal cancer","volume":"10","author":"Ogino","year":"2008","journal-title":"J. Mol. Diagn"},{"key":"B44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrg2957","article-title":"Enhancer function: new insights into the regulation of tissue-specific gene expression","volume":"12","author":"Ong","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41388-025-03453-6","article-title":"Brd4 regulates Pai-1 expression in tumor-associated macrophages to drive chemoresistance in colorectal cancer","volume":"44","author":"Pan","year":"2025","journal-title":"Oncogene"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-15-0876","article-title":"Plasminogen activator Inhibitor-1 in cancer: Rationale and insight for future therapeutic testing","volume":"75","author":"Placencio","year":"2015","journal-title":"Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"120536","DOI":"10.1016\/j.ijpharm.2021.120536","article-title":"Brd4 targeting nanotherapy prevents lipopolysaccharide induced acute respiratory distress syndrome","volume":"601","author":"Pooladanda","year":"2021","journal-title":"Int. J. Pharm."},{"key":"B48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/359235a0","article-title":"Apc mutations occur early during colorectal tumorigenesis","volume":"359","author":"Powell","year":"1992","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"758","DOI":"10.33594\/000000053","article-title":"Dual Pi3k-Brd4 inhibitor Sf1126 inhibits colorectal cancer cell growth in vitro and in vivo","volume":"52","author":"Qin","year":"2019","journal-title":"Cell Physiol. Biochem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41419-020-03015-6","article-title":"The therapeutic effect of the Brd4-Degrading protac A1874 in human Colon cancer cells","volume":"11","author":"Qin","year":"2020","journal-title":"Cell Death Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drudis.2017.09.011","article-title":"Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors","volume":"23","author":"Ramadoss","year":"2018","journal-title":"Drug Discov. Today"},{"key":"B52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00262-020-02665-x","article-title":"Selective bet-bromodomain inhibition by Jq1 suppresses dendritic cell maturation and antigen-specific T-Cell responses","volume":"70","author":"Remke","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00109-011-0837-0","article-title":"Aberrant epigenetic regulation of bromodomain Brd4 in human Colon cancer","volume":"90","author":"Rodriguez","year":"2012","journal-title":"J. Mol. Med. Berl."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1053\/j.gastro.2019.12.052","article-title":"Principles for evaluation of surveillance after removal of colorectal polyps: recommendations from the world endoscopy organization","volume":"158","author":"Rutter","year":"2020","journal-title":"Gastroenterology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1074\/jbc.M111.282855","article-title":"Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor B from inactive ribonucleoprotein complexes","volume":"287","author":"Schroder","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-020-02653-1","article-title":"Romidepsin (Fk228) regulates the expression of the immune checkpoint ligand Pd-L1 and suppresses cellular immune functions in Colon cancer","volume":"70","author":"Shi","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"760789","DOI":"10.3389\/fonc.2021.760789","article-title":"Inhibition of bromodomain and extra terminal (Bet) domain activity modulates the Il-23r\/Il-17 axis and suppresses acute graft-versus-host disease","volume":"11","author":"Snyder","year":"2021","journal-title":"Front. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2025-335412","DOI":"10.1136\/gutjnl-2025-335412","article-title":"Current and emerging concepts for systemic treatment of metastatic colorectal cancer","author":"Steup","year":"2025","journal-title":"Gut"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1182\/blood-2014-08-598037","article-title":"Bet bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice","volume":"125","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/ng1330","article-title":"Epigenetic inactivation of sfrp genes allows constitutive wnt signaling in colorectal cancer","volume":"36","author":"Suzuki","year":"2004","journal-title":"Nat. Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.2147\/DDDT.S180976","article-title":"Arsenic sulfide amplifies Jq1 toxicity via mitochondrial pathway in gastric and Colon cancer cells","volume":"12","author":"Tan","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1158\/0008-5472.CAN-18-3223","article-title":"Bet inhibitors potentiate chemotherapy and killing of Spop-Mutant Colon cancer cells via induction of Dr5","volume":"79","author":"Tan","year":"2019","journal-title":"Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The bet family in immunity and disease","volume":"6","author":"Wang N.","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1038\/s41467-021-24687-4","article-title":"Stromal induction of Brd4 phosphorylation results in chromatin remodeling and bet inhibitor resistance in colorectal cancer","volume":"12","author":"Wang W.","year":"2021","journal-title":"Nat. Commun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"Bet bromodomain proteins function as master transcription elongation factors independent of Cdk9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol. Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.toxlet.2023.08.009","article-title":"Bromodomain protein 4 mediates the roles of TGF\u03b21-induced Stat3 signaling in mouse liver fibrogenesis","volume":"385","author":"Xu","year":"2023","journal-title":"Toxicol. Lett."},{"key":"B69","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4161\/epi.4.5.9371","article-title":"Epigenetic disruption of the WNT\/\u00df-catenin signaling pathway in human cancers","volume":"4","author":"Ying","year":"2009","journal-title":"Epigenetics"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1433315","DOI":"10.3389\/fimmu.2024.1433315","article-title":"Immunotherapy for colorectal cancer","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"108498","DOI":"10.1016\/j.intimp.2021.108498","article-title":"The suppression of Brd4 inhibits peripheral plasma cell differentiation and exhibits therapeutic potential for systemic lupus erythematosus","volume":"103","author":"Zeng","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"43137","DOI":"10.1074\/jbc.M112.413047","article-title":"Bromodomain-containing protein 4 (Brd4) regulates Rna polymerase Ii serine 2 phosphorylation in human Cd4+ T cells","volume":"287","author":"Zhang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.7150\/ijbs.34162","article-title":"Brd4 inhibitor Azd5153 suppresses the proliferation of colorectal cancer cells and sensitizes the anticancer effect of parp inhibitor","volume":"15","author":"Zhang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41389-020-0218-z","article-title":"Bet protein inhibitor Jq1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating Runx2\/Nid1 signaling","volume":"9","author":"Zhou","year":"2020","journal-title":"Oncogenesis"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1682223\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:54:27Z","timestamp":1762941267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1682223\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":74,"alternative-id":["10.3389\/fphar.2025.1682223"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1682223","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"article-number":"1682223"}}